# BIOFLOW-china Post-marketing Study (BIOTRONIK)

> **NCT05667285** · — · TERMINATED · sponsor: **Biotronik (Beijing) Medical Device Ltd.** · enrollment: 122 (actual)

## Conditions studied

- In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Native Coronary Artery Stenosis

## Interventions

- **DEVICE:** BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System

## Key facts

- **NCT ID:** NCT05667285
- **Lead sponsor:** Biotronik (Beijing) Medical Device Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-02
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 122 (ACTUAL)
- **Why stopped:** According to the renewal registration certificate requirements issued by the NMPA, this product does not need to collect post-market safety data.
- **Last updated:** 2024-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667285, "BIOFLOW-china Post-marketing Study (BIOTRONIK)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05667285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*